1026364-71-5

Basic information

• Product Name: (S)-2-[(1-tert-Butoxycarbonylamino-cyclopentanecarbonyl)-amino]-4-phenyl-butyric acid ethyl ester
• Synonyms: (S)-2-[(1-tert-Butoxycarbonylamino-cyclopentanecarbonyl)-amino]-4-phenyl-butyric acid ethyl ester
• CAS NO: 1026364-71-5
• Molecular Weight: 418.533
• Mol File: 1026364-71-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-2-[(1-tert-Butoxycarbonylamino-cyclopentanecarbonyl)-amino]-4-phenyl-butyric acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-[(1-tert-Butoxycarbonylamino-cyclopentanecarbonyl)-amino]-4-phenyl-butyric acid ethyl ester(1026364-71-5)
• EPA Substance Registry System: (S)-2-[(1-tert-Butoxycarbonylamino-cyclopentanecarbonyl)-amino]-4-phenyl-butyric acid ethyl ester(1026364-71-5)

Safety Data

• Hazardous Substances Data: 1026364-71-5(Hazardous Substances Data)

Upstream product

• 35264-09-6 1-(tert-butoxycarbonylamino)cyclopentanecarboxylic acid 
• 46460-23-5 ethyl 2-amino-4-phenyl-(2S)-butyrate 

Downstream Products

• 169319-53-3 (S)-2-{[1-((S)-2-Acetylsulfanyl-3-methyl-butyrylamino)-cyclopentanecarbonyl]-amino}-4-phenyl-butyric acid ethyl ester 

Relevant articles and documents

New α-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11

Dual inhibitors of the two zinc metallopeptidases, neutral endopeptidase (NEP, EC 3.4.24.11) and angiotensin-I converting enzyme, have been the focus of much clinical interest for the treatment of hypertension and congestive heart failure. A novel series of α-thio dipeptides containing central cyclic non-natural amino acids were prepared and were evaluated for their ability to inhibit these two metallopeptidases in vitro and in vivo. Most of these compounds were found to be excellent dual inhibitors of ACE and NEP in vitro and several were also found to inhibit angiotensin-I (AI) pressor response in conscious rats when given by intravenous administration. Compound 6n, one of our most potent dual inhibitors in vitro, was found to be more efficacious than captopril in the AI pressor experiment when administered orally to conscious rats. This compound was also found to inhibit plasma NEP activity following oral administration to conscious rats and was more efficacious than acetorphan. The structure-activity relationships and biological activity of these dual inhibitors will be discussed.